Leman Biotech Co., Ltd. (referred to as "Leman Biotech") and Hangzhou Neoantigen Biotechnology Co., Ltd. (referred to as "Hangzhou Neoantigen") have recently entered into a collaboration to explore the potential of Meta 10 technology in the development of personalized neoantigen cancer vaccines.

Recently, Prof. Li Tang and Dr. Yugang Guo, founders of Leman Biotech, were invited to Shanghai Pharmaceuticals Group for a visit and exchange. They also visited the Shanghai Biomedical Frontier Industry Innovation Center and the Shanghai Tumor Cellular Therapy Technology Innovation Center, both of which are under construction. Mr. Min Zuo, the former president of Shanghai Pharmaceuticals and chairman of the Shanghai Biomedical Industry Equity Investment Fund, warmly welcomed the Leman Biotech team and participated in a symposium.

Leman Biotech Co., Ltd. (hereinafter referred to as "Leman Biotech"), an innovative metabolic immunotherapy research and development company, has announced a comprehensive strategic cooperation agreement with Chengdu Ucello Biotechnology Co., Ltd. (hereinafter referred to as " Ucello Therapeutics"). Both companies will actively explore the translational applications of metabolic reprogramming technology (Meta 10) in universal CAR T cells.

Leman Biotech Co., Ltd., a clinical-stage biotechnology company focusing on development, production, and commercialization of innovative metabolic immunotherapies, has entered into a comprehensive strategic cooperation agreement with Nanjing Kati Medical Technology Co. Ltd., a leading biotech company in the development of next-generation CAR-T for solid tumors. The two parties will explore the application and translational capability of metabolic reprogramming technology (Meta 10) in CAR-T therapies with a focus on the treatment of solid tumors, and jointly advance the development of cell therapy industry.

Leman Biotech Co., Ltd. (hereinafter referred to as "Leman Biotech"), a clinical-stage biotechnology company focusing on development, production, and commercialization of innovative metabolic immunotherapies, has signed a comprehensive strategic cooperation agreement with Xiangxue Life Science Technology (Guangdong) Co., Ltd. (hereinafter referred to as "Xiangxue Life Sciences"). The two parties will apply their respective technological advantages to fully explore the combined application of Meta 10 metabolic reprogramming technology and TCR-T cell therapy products in the treatment of solid tumors.

Recently, a breakthrough result was achieved in an IIT clinical study of Leman Biotech’s metabolically enhanced CD19 CAR-T injection, with the first patient achieving complete remission after treatment at a very low dose. The results received widespread attention from medias and investors, and the co-founder of Leman Biotech was interviewed by media “Intellectual Medicine Bureau” to share the specifics of the clinical study and how AI can be incorporated into next-generation solid tumor CAR-T design as the follows.

On May 25, at the China AI Drug Discovery Conference held in Shanghai, Dr. Jian Ma, co-founder and CEO of XtalPi, hosted the brand launch event of XtalPi Pharma under the theme of "Smart New Life, Leading the Future." XtalPi Pharma is an exclusive brand focusing on early-stage R&D of innovative drugs, powered by advanced AI technology. It boasts two distinct technology platforms: ID4Inno™ for innovative small molecule discovery and XupremAb™ for next-generation innovative large molecule discovery.

Leman Biotech Co., Ltd. (referred to as "Leman Biotech" or "the company") is pleased to announce the successful treatment of the first patient using its metabolically enhanced CD19 CAR-T therapy (Meta10-19). The patient, enrolled in an investigator-initiated trial (IIT) at the First Affiliated Hospital of the University of Science and Technology of China, has achieved complete remission and was subsequently discharged from the hospital. This clinical trial (NCT05715606) was officially initiated in early 2023 to evaluate the safety and efficacy of Leman Biotech's Metabolically Enhanced CAR-T System. The CD19, a well-studied antigen, was chosen as the therapeutic target to gather preliminary clinical data and accelerate the development of future metabolically enhanced CAR-T cell therapies for solid tumors.